Novartis' Myfortic Placed On China's National Drug Reimbursement List, Strengthens Portfolio On Immunosuppressant Therapy
This article was originally published in PharmAsia News
SHANGHAI - Novartis immunosuppressant therapy Myfortic (mycophenolate sodium) was recently added to China's revised National Drug Reimbursement List
You may also be interested in...
China's Next Round Of Drug Price Cuts? NDRC To Slash Prices On More Products On National Drug Reimbursement List
SHANGHAI - China's New Drug Price Guidelines are expected to be released by the end of this year, which are likely to lead to another round of price cuts on drugs included on the National Drug Reimbursement List, according to analysts
BEIJING - In the government's latest move to expand coverage under sweeping health system reforms that are in the works China-wide, the Ministry of Human Resources and Social Security has added hundreds of new medicines to the latest edition of the national drug reimbursement catalog
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).